Results 331 to 340 of about 1,175,170 (409)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Dynamic Changes of Immunoreactive CD34, CD117, and CD41 Hematopoietic Stem Cells in Human Placentas of Different Gestational Ages. [PDF]

J Dev Biol
Jovicic S, Nikolic IR, Amidžić L, Ljubojevic V, Barudzija M, Skrbic R.   +5 more
europepmc   +1 more source

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells [PDF]

, 2019
Chen, Yi-Bin, DiPersio, John F., et al,
core   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Comparative circRNA Profiling in Human Erythroblasts Derived from Fetal Liver and Bone Marrow Hematopoietic Stem Cells Using Public RNA-Seq Data. [PDF]

Int J Mol Sci
Habara A.
europepmc   +1 more source

Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure – interaction between loss of Y chromosome and clonal haematopoiesis

European Journal of Heart Failure, EarlyView.
Abstract Aims Age‐associated clonal haematopoiesis of indeterminate potential (CHIP) has been linked to increased incidence and worse prognosis of chronic heart failure (CHF). CHIP arises from somatic mutations in haematopoietic stem and progenitor cells. Mosaic loss of Y chromosome (LOY), the most common somatic mutation in male blood cells, increases
Sebastian Cremer, Moritz von Scheidt, Klara Kirschbaum, Lukas Tombor, Silvia Mas‐Peiro, Wesley Abplanalp, Tina Rasper, Akshay Ware, Andrin Schuff, Alexander Berkowitsch, Johannes Krefting, David Leistner, Heribert Schunkert, Thimoteus Speer, Stefanie Dimmeler, Andreas Michael Zeiher   +15 more
wiley   +1 more source

Niche-derived Semaphorin 4A safeguards functional identity of myeloid-biased hematopoietic stem cells. [PDF]

Nat Aging
Toghani D, Gupte S, Zeng S, Mahammadov E, Crosse EI, Seyedhassantehrani N, Burns C, Gravano D, Radtke S, Kiem HP, Rodriguez S, Carlesso N, Pradeep A, Georgiades A, Lucas F, Wilson NK, Kinston SJ, Göttgens B, Zong L, Beerman I, Park B, Janssens DH, Jones D, Toghani A, Nerlov C, Pietras EM, Mesnieres M, Maes C, Kumanogoh A, Worzfeld T, Cheong JG, Josefowicz SZ, Kharchenko P, Scadden DT, Scialdone A, Spencer JA, Silberstein L.   +36 more
europepmc   +1 more source

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source

Sirens and sphingolipids: What lures hematopoietic stem cells to the nervous system? [PDF]

Mol Ther
Li Y, Eichler FS.
europepmc   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin, Johann Bauersachs, Magdy Abdelhamid, Suleman Aktaa, Hussam Al Ghorani, Antonio Bayes‐Genis, Jan Biegus, Michael Böhm, Javed Butler, Nicolas Girerd, Marco Metra, Wilfried Mullens, Hadi Skouri, Muthiah Vaduganathan, Seif El Hadidi, Giuseppe M.C. Rosano, Gianluigi Savarese   +16 more
wiley   +1 more source